"We are working towards not just hitting the cancer cells but also the immune suppression in the tumor. Immune suppression is one of the biggest causes of the current treatments not working."
"The American health authorities in the USA have considered our treatment to be groundbreaking and promising that we must now embark on a major registration study in mother brand strength."
Mai-Britt Zocca, IO Biotech CEO, Denmark's EY Entrepreneur of the Year.
Don't let Staehelin throw you under the bus on this one Corpus.